As Biotechnology companies, Cellectis S.A. (NASDAQ:CLLS) and Insmed Incorporated (NASDAQ:INSM) are our subject to contrast. And more specifically their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis S.A.	21.43M	38.31	78.69M	-2.11	0.00
Insmed Incorporated	9.84M	252.46	324.28M	-4.22	0.00

Table 1 highlights Cellectis S.A. and Insmed Incorporated’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us Cellectis S.A. and Insmed Incorporated’s return on equity, return on assets and net margins.

	Net Margins	Return on Equity	Return on Assets
Cellectis S.A.	-367.20%	-23%	-18.8%
Insmed Incorporated	-3,295.53%	-99.4%	-46.9%

Risk & Volatility

Cellectis S.A.’s current beta is 1.74 and it happens to be 74.00% more volatile than S&P 500. Competitively, Insmed Incorporated’s beta is 3.08 which is 208.00% more volatile than S&P 500.

Liquidity

The Current Ratio and a Quick Ratio of Cellectis S.A. are 11.2 and 11.2. Competitively, Insmed Incorporated has 6.5 and 6.4 for Current and Quick Ratio. Cellectis S.A.’s better ability to pay short and long-term obligations than Insmed Incorporated.

Analyst Recommendations

The table given features the ratings and recommendations for Cellectis S.A. and Insmed Incorporated.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Cellectis S.A.	0	2	1	2.33
Insmed Incorporated	0	1	7	2.88

$35.25 is Cellectis S.A.’s average price target while its potential upside is 80.58%. On the other hand, Insmed Incorporated’s potential upside is 26.34% and its average price target is $40.43. The results from earlier shows that analysts view suggest that Cellectis S.A. seems more appealing than Insmed Incorporated.

Institutional & Insider Ownership

The shares of both Cellectis S.A. and Insmed Incorporated are owned by institutional investors at 29.4% and 0% respectively. Comparatively, 1% are Insmed Incorporated’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Cellectis S.A.	12.66%	10.81%	-10.39%	-33.67%	-37.98%	17.6%
Insmed Incorporated	1.85%	22.42%	66.16%	37.84%	22.92%	126.83%

For the past year Cellectis S.A. was less bullish than Insmed Incorporated.

Summary

On 9 of the 12 factors Cellectis S.A. beats Insmed Incorporated.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companyÂ’s products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The companyÂ’s lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.